August 6, 2025 — Leads & Copy — MAX BioPharma, Inc. and Revilico, Inc. have announced a collaboration to study the mechanisms of action, lead optimization, and identification of molecular targets of MAX BioPharma’s oxysterol-based drug candidates. Revilico will utilize its AI-enabled, end-to-end drug discovery platform.
“We are extremely excited about forming this important collaboration…that will empower MAX BioPharma in its efforts to develop novel drugs…for several human diseases,” said Farhad Parhami, President and CEO of MAX BioPharma. Frank Stappenbeck, Director of Chemistry at MAX BioPharma, added that Revilico’s structure-based drug discovery technologies can add value to their programs.
Christopher Korban, CEO of Revilico, explained that their operating system, driven by physics, informed by multi-omics, and enhanced by AI, can aid drug development efforts. Christian Chung, CSO of Revilico, added that combining their AI-enabled discovery software with MAX BioPharma’s disease-targeted platforms will improve hit-to-lead timelines.
MAX BioPharma is a preclinical stage biopharmaceutical company developing novel small molecule lipids as drug candidates. Revilico has developed a unified Operating System capable of multi-omics analyses at scale, physics-based dynamics modeling, virtual cells, generative chemistry, quantum chemistry, and AI-agent workflows.
Farhad Parhami, President and CEO, MAX BioPharma, fparhami@maxbiopharma.com
Christopher Korban, CEO, Revilico, christopher.korban@revilico.bio
Source: MAX BioPharma, Inc.
